Eli Lilly’s Ebglyss (lebrikizumab-lbkz ... Bambusa Therapeutics has announced the dosing of its first healthy volunteers as part of a Phase I trial on its half-life extended bispecific antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback